• Salah-Eddin Al-Batran, Hans-Gerd Meerpohl, Gunter von Minckwitz, Akin Atmaca, Ulrich Kleeberg, Nadia Harbeck, Werner Lerbs, Detlef Hecker, Jalid Sehouli, Alexander Knuth, and Elke Jager.
• Krankenhaus Nordwest, Frankfurt, Deutschland. albatran@aol.com
• Oncology. 2006 Jan 1; 70 (2): 141-6.

PurposeThe aim of this study was to assess whether the reduction in the total dose of pegylated liposomal doxorubicin (PLD) per cycle from 50 mg/m(2) every 4 weeks to 40 mg/m(2) every 4 weeks can effectively lower the incidence of treatment-related palmar-plantar erythrodysesthesia (PPE) and mucositis.MethodsPatients received PLD 40 mg/m(2) every 4 weeks, and were evaluated for toxicity prior to each treatment and for response every 8 weeks.ResultsAll patients were previously treated with at least one chemotherapy regimen for metastatic disease, and 72% of the patients had a prior exposure to an anthracycline. Forty-six evaluable patients received a median of four PLD cycles, with a median dose intensity of 10 mg/m(2)/week and a median cumulative dose of 160 mg/m(2). No National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade 3 or 4 PPE was observed in these patients. NCI-CTC grade 3 or 4 mucositis occurred in 4.3% of patients, only. Response rates and survival results observed here were comparable to those observed with PLD 50 mg/m(2) every 4 weeks in a matched patient population. However, patients treated with PLD 40 mg/m(2) every 4 weeks experienced less PPE and mucositis and required clearly less dose reductions and treatment delays.ConclusionThe favorable safety profile observed in this study leads us to recommend the use of PLD 40 mg/m(2) every 4 weeks for patients with advanced breast cancer.Copyright 2006 S. Karger AG, Basel.

34 keywords...

hide…